Arora Nikita, Knowles Sandra, Gomes Tara, Mamdani Muhammad M, Juurlink David N, Carlisle Corine, Tadrous Mina
1 McMaster University, Hamilton, Ontario.
2 The Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario.
Can J Psychiatry. 2016 Dec;61(12):758-765. doi: 10.1177/0706743716649190. Epub 2016 Jul 10.
Although antidepressants and antipsychotics are valuable medications in the treatment of select psychiatric disorders, there is increasing focus on the balance of risks and benefits of these drugs as prescribed, particularly in the pediatric population. We examined recent national trends and interprovincial variation in dispensing of antipsychotic and antidepressant prescriptions to the Canadian pediatric population.
We conducted a population-based cross-sectional study of antidepressant and antipsychotic prescriptions dispensed by Canadian pharmacies to the pediatric population (≤18 years) between 2010 and 2013. Prescription volumes were obtained from IMS Health. Analysis was stratified by drug, year, quarter, and province and population-standardized using age-adjusted population estimates.
From the first quarter of 2010 to the fourth quarter of 2013, dispensing of antipsychotics to the pediatric population increased 33% (from 34 to 45 prescriptions per 1000) and dispensing of antidepressants increased 63% (from 34 to 55 per 1000). We observed a 1.5-fold interprovincial difference in dispensing rates for antidepressants (range: 189 per 1000 to 275 per 1000) and a 3.0-fold difference for antipsychotics (range: 85 per 1000 to 253 per 1000) in 2013. Among antidepressants, selective serotonin reuptake inhibitors were the most dispensed (76%), with fluoxetine being the leading agent. Among antipsychotics, atypical antipsychotics were the most dispensed (97%), with risperidone being the leading agent.
Antipsychotic and antidepressant dispensing to the Canadian pediatric population increased from 2010 to 2013, with considerable interprovincial variation. Future research is required to explore reasons for observed patterns to optimize care for the Canadian pediatric population.
尽管抗抑郁药和抗精神病药是治疗某些精神疾病的重要药物,但人们越来越关注这些药物按处方使用时的风险效益平衡,尤其是在儿科人群中。我们研究了加拿大儿科人群抗精神病药和抗抑郁药处方配药的近期全国趋势及省际差异。
我们对2010年至2013年加拿大药房为儿科人群(≤18岁)配出的抗抑郁药和抗精神病药处方进行了一项基于人群的横断面研究。处方量数据来自艾美仕市场研究公司(IMS Health)。分析按药物、年份、季度和省份进行分层,并使用年龄调整后的人口估计数进行人口标准化。
从2010年第一季度到2013年第四季度,儿科人群的抗精神病药配药量增加了33%(从每1000人34张处方增至45张),抗抑郁药配药量增加了63%(从每1000人34张处方增至55张)。2013年,我们观察到抗抑郁药配药率存在1.5倍的省际差异(范围:每1000人189张至275张),抗精神病药配药率存在3.0倍的差异(范围:每1000人85张至253张)。在抗抑郁药中,选择性5-羟色胺再摄取抑制剂的配药量最高(76%),氟西汀是主要药物。在抗精神病药中,非典型抗精神病药的配药量最高(97%),利培酮是主要药物。
2010年至2013年,加拿大儿科人群的抗精神病药和抗抑郁药配药量增加,且存在显著的省际差异。需要进一步研究以探究观察到的模式背后的原因,从而优化对加拿大儿科人群的护理。